What analyst predict for Arrowhead Pharmaceuticals NASDAQ:ARWR ?
Arrowhead Pharmaceuticals headquartered in Pasadena, California, United States is reporting their earnings on 12/11/2018 after the bell. Street forecast for the quarter ending Sep 2018 is $-0.17.
According to stock market daily analyst this is Lower then same time previous year.Arrowhead Pharmaceuticals, reported EPS for the same quarter last year was $-0.14.
About Arrowhead Pharmaceuticals NASDAQ:ARWR
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The depth and versatility of our RNAi technologies enable us to address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise druggable by small molecules and biologics.
Arrowhead has built an experienced team of leaders that foster a culture of innovation and have a proven ability to advance development programs from idea stage into commercial pharmaceutical products.
|% Change from 52 Week Low|
|% Change from 52 Week High|